PersonFounderInvestor
Tom Cahill
Thomas J. Cahill, MD, PhD is the founder and managing partner of Newpath Partners, a Boston-based life sciences venture firm he built from the ground up to translate breakthrough academic science into medicines. A structural biologist trained under two Nobel laureates, Cahill has co-founded more than a dozen biotech companies — including Prime Medicine, Chroma Medicine, and Autobahn Therapeutics — and became one of the pandemic's most consequential behind-the-scenes operators when he assembled Scientists to Stop COVID-19, a coalition that fed curated research directly to the White House and helped redirect Regeneron's manufacturing to Dublin.
venture-capitalbiotechlife-sciencescrisprgene-editingnewpath-partners
